Femtobiomed Overview

  • Founded
  • 2011

Founded
  • Status
  • Public

  • Employees
  • 14

Employees
  • Stock Symbol
  • 327610

Stock Symbol
  • Share Price
  • $10.05

  • (As of Friday Closing)

Femtobiomed General Information

Description

Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
KRX
Primary Office
  • 17 Pangyoro-228-beon-gil
  • Bundang-gu
  • Seongnam-si, Gyeonggi-do
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Femtobiomed Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.05 $10.56 $7.21 - $15.45 $84.5M 8.4M 1.58K -$0.97

Femtobiomed Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 124,939 124,939 89,342 45,048
Revenue 201 201 212 181
EBITDA (7,590) (7,590) (2,579) (3,439)
Net Income (8,151) (8,151) (3,024) (3,901)
Total Assets 3,851 3,851 2,105 4,341
Total Debt 301 301 562 309
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Femtobiomed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Femtobiomed‘s full profile, request access.

Request a free trial

Femtobiomed Patents

Femtobiomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3882332-A1 Method and apparatus for controlling intracellular delivery of materials Pending 12-Nov-2018 000000000
EP-3882332-A4 Method and apparatus for controlling intracellular delivery of materials Pending 12-Nov-2018 000000000 0
JP-6799086-B2 Method for quantifying hydrophobic components in liquid using contact surface diffusion coefficient and method for providing information for diagnosis of diseases using this method Active 26-Apr-2017 000000000
JP-2019521338-A Method of quantifying hydrophobic component in liquid using contact surface diffusion coefficient and method of providing information for diagnosis of disease using the same Active 26-Apr-2017 000000000
US-20190032000-A1 Device for putting material into cell Inactive 28-Dec-2014 C12M35/02 0
To view Femtobiomed’s complete patent history, request access »

Femtobiomed Executive Team (2)

Name Title Board Seat Contact Info
Sang-Hyun Lee Ph.D Founder & Co-Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

Femtobiomed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial